Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
Sponsor: National Institute on Drug Abuse (NIDA)
Suspended
Funding
A PHASE3 clinical study on Cocaine Use Disorder, this trial is suspended. The trial is conducted by National Institute on Drug Abuse (NIDA) and has accumulated 12 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jul 2022 — Jun 2023 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Apr 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2021 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Dec 2018 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jul 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jul 2018 [monthly]
Recruiting PHASE3
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Drug Abuse (NIDA)
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .